杨新春

• 1:首都医科大学附属北京朝阳医院心脏中心

摘要(Abstract)：

<正>心房颤动(房颤)是临床上最常见的持续性快速心律失常之一,因可产生严重临床事件而受到人们的高度关注。据估算,在2010年世界上有2090万男性房颤患者,1260万女性房颤患者;在欧洲,到2030年将会有1400万~1700万房颤患者,每年将新增加12万~21.5万确诊房颤患者。在20岁以上人群中,房颤发生率大约为3%[1-2];在高龄、

关键词(KeyWords)： 心房颤动;指南解读

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 杨新春

参考文献(References)：

• [1]Bj9rck S,Palaszewski B,Friberg L,et al.Atrial fibrillation,stroke risk,and warfarin therapy revisited:a population-based study.Stroke,2013,44(11):3103-3108.
• [2]Haim M,Hoshen M,Reges O,et al.Prospective national study of the prevalence,incidence,management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation.J Am Heart Assoc,2015,4(1):e001486.
• [3]Kirchhof P,Benussi S,Kotecha D,er al.2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.Europace,2016,18(11):1609-1678.
• [4]Camm AJ,Kirchhof P,Lip GY,et al.Guidelines for the management of atrial fibrillation:the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC).Eur Heart J,2010,31(19):2369-2429.
• [5]Camm AJ,Lip GY,De Caterina R,et al.2012 focused update of the ESC Guidelines for the management of atrial fibrillation:an update of the 2010 ESC Guidelines for the management of atrial fibrillation.Developed with the special contribution of the European Heart Rhythm Association.Eur Heart J,2012,33(21):2719-2747.
• [6]Benjamin EJ,Wolf PA,D'Agostino RB,et al.Impact of atrial fibrillation on the risk of death:the Framingham Heart Study.Circulation,1998,98(10):946-952.
• [7]Stewart S,Hart CL,Hole DJ,et al.A population-based study of the long-term risks associated with atrial fibrillation:20-year follow-up of the Renfrew/Paisley study.Am J Med,2002,113(5):359-364.
• [8]Andersson T,Magnuson A,Bryngelsson IL,et al.All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008:a Swedish nationwide long-term casecontrol study.Eur Heart J,2013,34(14):1061-1067.
• [9]Kotecha D,Holmes J,Krum H,et al.Efficacy ofβblockers in patients with heart failure plus atrial fibrillation:an individualpatient data meta-analysis.Lancet,2014,384(9961):2235-2243.
• [10]Steinberg BA,Kim S,Fonarow GC,et al.Drivers of hospitalization for patients with atrial fibrillation:Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation(ORBIT-AF).Am Heart J,2014,167(5):735-742.
• [11]Kirchhof P,Schmalowsky J,Pittrow D,et al.Management of patients with atrial fibrillation by primary-care physicians in Germany:1-year results of the ATRIUM registry.Clin Cardiol,2014,37(5):277-284.
• [12]Bajaj NS,Parashar A,Agarwal S,et al.Percutaneous left atrial appendage occlusion for stroke prophylaxis in nonvalvular atrial fibrillation:a systematic review and analysis of observational studies.JACC Cardiovasc Interv,2014,7(3):296-304.
• [13]Lewalter T,Kanagaratnam P,Schmidt B,et al.Ischaemic stroke prevention in patients with atrial fibrillation and high bleeding risk:opportunities and challenges for percutaneous left atrial appendage occlusion.Europace,2014,16(5):626-630.
• [14]Meier B,Blaauw Y,Khattab AA,et al.EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion.Europace,2014,16(10):1397-1416.
• [15]Holmes DR Jr,Kar S,Price MJ,et al.Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy:the PREVAIL trial.J Am Coll Cardiol,2014,64(1):1-12.
• [16]Di Biase L,Mohanty P,Mohanty S,et al.Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device:Results From the AATAC Multicenter Randomized Trial.Circulation,2016,133(17):1637-1644.
• [17]Jones DG,Haldar SK,Hussain W,et al.A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure.J Am Coll Cardiol,2013,61(18):1894-1903.
• [18]Anselmino M,Matta M,D'Ascenzo F,et al.Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction:a systematic review and meta-analysis.Circ Arrhythm Electrophysiol,2014,7(6):1011-1018.
• [19]Hunter RJ,Berriman TJ,Diab I,et al.A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure(the CAMTAF trial)Circ Arrhythm Electrophysiol,2014,7(1):31-38.
• [20]Mac Donald MR,Connelly DT,Hawkins NM,et al.Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction:a randomised controlled trial.Heart,2011,97(9):740-747.